Quince Therapeutics, Inc. (QNCX)

Market Cap	96.95M
Revenue (ttm)	n/a
Net Income (ttm)	-49.03M
Shares Out	53.71M
EPS (ttm)	-1.10
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	205,186
Open	1.750
Previous Close	1.780
Day's Range	1.660 - 1.851
52-Week Range	0.690 - 2.450
Beta	1.08
Analysts	Strong Buy
Price Target	8.00 (+343.21%)
Earnings Date	Nov 12, 2025

About QNCX

Quince Therapeutics, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing therapeutics for patients with debilitating and rare diseases. The company’s lead asset candidature comprises EryDex for the treatment of rare pediatric neurodegenerative disease, including A-T, an inherited autosomal recessive neurodegenerative and immunodeficiency disorder caused by mutations in ATM gene. Its AIDE technology platform, a drug/device combination platform that uses an automated process to encapsulate a drug into a patien...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: May 9, 2019
• Employees: 36
• Stock Exchange: NASDAQ
• Ticker Symbol: QNCX
• Website: https://www.quincetx.com

Analyst Summary

According to 6 analysts, the average rating for QNCX stock is "Strong Buy." The 12-month stock price target is $8.0, which is an increase of 343.21% from the latest price.

Price Target

$8.0

(343.21% upside)

Analyst Consensus: Strong Buy